Efectividad y seguridad de regorafenib y trifluridina/tipiracilo en cáncer colorrectal metastático - ILAPHAR | Revista de la OFIL
Indirect analysis of adverse events. (1) Regorafenib vs TAS-102. (2)... | Download Scientific Diagram
Regorafenib TAS-102 or TAS-102 Regorafenib - ppt download
A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer - Guan-Li Su, Yuan-Yuan Wang, Jin-Cheng Wang, Hao Liu, 2020
Hospitalization-associated regorafenib or TAS-102 discontinuation. | Download Scientific Diagram
A Comparison of Regorafenib and TAS‐102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta‐analysis | Semantic Scholar
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies | Anticancer Research
A Comparison of Regorafenib and TAS‐102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta‐analysis | Semantic Scholar
PDF) A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts) | A. El-khoueiry - Academia.edu
Treatment Planning for Metastatic Colorectal Carcinoma with STIVARGA® ( regorafenib) | Global HCP Website
STIVARGA or Trifluridine/Tipiracil in Third-Line Therapy? | Stivarga Global Website
Efectividad y seguridad de regorafenib y trifluridina/tipiracilo en cáncer colorrectal metastático - ILAPHAR | Revista de la OFIL
Cost‐effectiveness Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer in the United States | Semantic Scholar
Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies | Anticancer Research
Cancers | Free Full-Text | Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
P-159 Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chem
A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis - ScienceDirect
Differences and similarities between regorafenib and TAS-102 trials. | Download Table
A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer - Guan-Li Su, Yuan-Yuan Wang, Jin-Cheng Wang, Hao Liu, 2020
A Comparison of Regorafenib and TAS‐102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta‐analysis | Semantic Scholar
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States in: Journal of the National Comprehensive Cancer Network Volume 21 Issue 3 (2023)
